Effect of Risperidone and Fluoxetine on the Movement and Neurochemical Changes of Zebrafish by Prieto, María Jimena et al.
Open Journal of Medicinal Chemistry, 2012, 2, 129-138 
doi:10.4236/ojmc.2012.24016 Published Online December 2012 (http://www.SciRP.org/journal/ojmc) 
Effect of Risperidone and Fluoxetine on the Movement  
and Neurochemical Changes of Zebrafish 
Maria Jimena Prieto1,2*, Hector Carreño Gutierrez3, Rosario Arévalo Arévalo3,  
Nadia S. Chiaramoni1,2, Silvia del Valle Alonso1,2 
1Biomembrane Laboratory, Department of Science and Technology, National University of Quilmes, Buenos Aires, Argentina 
2IMBICE-CONICET, Buenos Aires, Argentina 
3Department of Cell Biology and Pathology, Institute of Neuroscience of Castilla y Leon, School of Medicine,  
University of Salamanca, Salamanca, Spain 
Email: *jprieto@unq.edu.ar 
 
Received September 20, 2012; revised October 23, 2012; accepted November 4, 2012 
ABSTRACT 
Brain developmental disorders in humans, including Autism Spectrum Disorders (ASD) and Down’s syndrome, have 
been linked to increased serotonin levels. This work was designed to study changes in serotonin levels in the early 
stages of development with two classes of antipsychotic drugs: Risperidone, a drug that blocks serotonin and dopamine 
receptors, and fluoxetine, a serotonin reuptake inhibitor. The use of antipsychotic drugs is a solid choice to study the 
decrease and increase of these neurotransmitters and their influence on development. The study of these parameters will 
give an idea of the effects of serotonin in early developmental stages. To this end, we examined the effects of risperi-
done and fluoxetine on the locomotor activity, heart rate and brain development of zebrafish larvae. Our results showed 
that in larvae exposed to fluoxetine alone, swimming was significantly increased at 9 dpf (days post-fertilization). Er-
ratic and abnormal movements were observed suggesting a toxic effect of fluoxetine. No erratic swimming was ob-
served in larvae treated with fluoxetine plus risperidone. Both drugs presented morphological changes in dopaminergic 
neurons and mononeurons. Exposure to fluoxetine plus risperidone indicated possible reversal effects. Studies in ze-
brafish allow obtaining new insights into the side effects of these drugs as well as into the brain control of locomotor 
activity. Testing several drug-induced changes in behavior and serotonin levels is one of the experimental approaches 
for screening a new therapeutically relevant compound, and thus, merits further research. 
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1. Introduction 
Serotonin has shown to play a role in regulating brain 
and spinal cord development before assuming its role as 
a neurotransmitter in the mature central nervous system 
(CNS) [1,2]. Serotonin plays an important role in modu-
lating motor pathways in all vertebrates. The early ap-
pearance of serotonin neurons and their wide distribution 
of extra-synaptic and synaptic terminals are consistent 
with the notion that serotonin acts as a growth factor or a 
signal molecule for multiple developmental mechanisms. 
Increased serotonin levels have also been linked to 
brain developmental disorders in humans, including Au- 
tism Spectrum Disorders (ASD) and Down’s syndrome 
[3-7]. ASD include different neurodevelopmental disor- 
ders that become manifest mainly in the earlier years of 
life [8] and affect the development of language, commu- 
nication, and reciprocal social interaction [9], with an 
incidence of 1 out of 150 individuals [10]. 
The main problem with the theory of serotonin as a 
primary cause of autism is that treatments which further 
increase serotonin levels seem to improve some symp- 
toms of autism, such as obsessiveness and social relat- 
edness [11], while the depletion of tryptophan, a sero- 
tonin precursor, seems to exacerbate autistic symptoms 
such as flapping, banging and self-hitting, rocking and 
increased anxiety [12]. 
On the other hand, a recent clinical study has reported 
that children exposed to therapeutic levels of a selective 
serotonin reuptake inhibitor (SSRI), such as is the case of 
fluoxetine, in the third trimester of pregnancy, scored 
lower in psychomotor and behavioral tests administered 
at 6 - 40 months of age compared to children who were 
not exposed to a SSRI during pregnancy [13]. Delays on 
psychomotor development and changes in movement and 
control at these later ages imply a more permanent prob- 
lem in motor circuitry. This is why more studies are need- 
ed to understand the neurochemistry of serotonin in the 
early stages of development. *Corresponding author. 
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Fluoxetine has many characteristics that make it a 
useful tool to study increases in serotonin neurotransmis- 
sion. Fluoxetine is one of several SSRIs used for treat- 
ment of clinical depression, anxiety disorder, obsesssive- 
compulsive disorder, and bulimia. It is also one of the 
most heavily prescribed antidepressant drugs world- 
wide. It is a potent and highly selective inhibitor of the 
transporter enzyme for serotonin reuptake at the presy- 
naptic membrane, causing an increase in serotonin con-
centrations at postsynaptic receptor sites [14]. 
On the other hand, atypical antipsychotic drugs, such 
as risperidone, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1- 
piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido 
[1,2-a] pyrimidin-4-one (Risp), have been increasingly 
used to treat anxiety-related disorders in addition to their 
use in the treatment of psychosis and ASD. Risperidone 
has been reported to act therapeutically by blocking se- 
rotonin and dopamine receptors [15]. This drug is useful 
to study increases in serotonin neurotransmission. Su et 
al. [16] showed that risperidone inhibits N-methyl-D- 
aspartate antagonist-induced glutamate release in the 
medial prefrontal cortex by blocking serotonin 5-HT2A 
receptors on glutamatergic terminals, leading to attenua-
tion of the activity of cortico-subcortical glutamatergic 
neurons. This attenuation, in turn, decreases MK-801-in- 
duced hyper-locomotion [16]. 
In this work, we used the zebrafish (Danio rerio) as an 
ideal model for studying developmental neurobiology 
and other fields of biomedicine. The zebrafish is a teleost 
of the Cyprinid family, and has very advantageous fea- 
tures to be used in the laboratory: its small size (no more 
than 5 cm in adults) allows the easy maintenance of sev- 
eral individuals with relatively low costs; females lay a 
large number of eggs; embryos develop rapidly and are 
semitransparent 24 hours post-fertilization (hpf); and 
embryos have a sequenced genome and numerous mutant 
and transgenic lines. 
It is known that serotonin plays an important role in 
modulating the motor output in vertebrates [17,18]. Se- 
rotonin neurons particularly innervate motor neurons 
projecting to axial muscles, which are associated with 
rhythmic locomotor movements. In developing zebrafish, 
serotonin neurons and projections appear in the hindbrain 
and spinal cord at about 2 days post-fertilization (dpf) [19]. 
Based on the above, the use of antipsychotic drugs is a 
solid choice to study the increase and decrease of this 
neurotransmitter and its influence on development. This 
study was designed to study changes in serotonin levels 
in the early stages of development induced by two 
classes of antipsychotic drugs: Risperidone, a drug that 
blocks serotonin and dopamine receptors; and fluoxetine, 
a serotonin reuptake inhibitor. To this end, we examined 
the effects of risperidone and fluoxetine on the locomotor 
activity, heart rate, and brain development of zebrafish 
larvae. Study of these parameters will give an idea of the 
effects caused by serotonin in early developmental stages. 
2. Materials and Methods 
2.1. Animals 
Adult zebrafish (Danio rerio) belonging to the AB line, 
provided by the Department of Cell Biology and Pathol- 
ogy, University of Salamanca, Spain, were used as breed- 
ing individuals. The animals were kept in tanks at a tem-
perature of 28˚C, with 14 h of light and 10 h of dark- 
ness, as previously established [20]. In this study, “em- 
bryos” refer to zebrafish prior to hatching (0 - 3 dpf), 
while “larvae” refer to post-hatch animals (over 3 dpf). 
Embryos were obtained from natural mating, and all em- 
bryos and larvae used in these experiments were reared at 
28.5˚C on a 14/10 h light/dark cycle in conditioned E3 
medium (NaCl 0.29 g/l, KCl 0.012 g, CaCl2 0.036 g/l and 
MgSO4 0.039 g/l in deionized water), and 50 ppb me- 
thylene blue (Panreac) to inhibit fungal growth. The ani- 
mals were handled following the European Union direc-
tives (86/609/EEC and 2003/65/EC) and Spanish legisla-
tion (RD 1201/2005, BOE 252/34367-91, 2005). 
Embryo Collection 
The evening before spawning, breeding pairs of speci- 
mens were transferred to rearing tanks. These tanks were 
kept at 28.5˚C. The first light stimulus after the dark cy- 
cle induced egg laying. The eggs obtained were prepared 
in petri dishes in E3 medium. Only the eggs that were 
fertilized and in good condition were selected for further 
treatment; the others were discarded. Egg observation 
was followed by stereomicroscopy (Leica Zoom, 2000). 
2.2. Exposure to Risperidone and Fluoxetine 
Risperdal tablets (Jannsen Cilag Laboratory, 2 mg ris- 
peridone) were dissolved in E3 medium and prepared as 
a 5 µM solution. Prozac tablets (Lilly Laboratory, 20 mg 
fluoxetine) were dissolved in E3 medium and prepared as 
a 5 µM solution. In Airhart et al. 2007 [7], zebrafish em-
bryos were exposed to seven different fluoxetine concen-
trations beginning at 10 pf and up to 11 dpf, to determine 
the lowest observable effective concentration (LOEC). In 
larvae exposed to 4.6 μM (LOEC) fluoxetine for 24 h 
intervals between 4 and 5 dpf, spontaneous swimming 
activity was significantly depressed compared to controls 
and remained depressed through 14 dpf. In addition, the 
core neural migration raphe to the spinal cord was ob-
served between 3 and 6 dpf [7] and serotonin levels 
could affect normal development of CNS. In this respect, 
in this work, we selected the following exposure concen-
trations: 1) Risp 5 µM at 4 dpf for 24 h; 2) Risp 5 µM at 
6 dpf for 24 h; 3) Prozac 5 µM at 4 dpf for 24 h; 4) Pro-
zac 5 µM at 4 dpf for 24 h and Risp 5 µM at 6 dpf for 24 
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h. Controls were untreated larvae. Larvae were exposed 
to 5 μM risperidone or fluoxetine for periods of 24 h at 4 
or 6 dpf and subsequently rescued into a preconditioned 
E3 medium (Figure 1). 
2.3. Behavioral Testing: Spontaneous Swimming  
Activity (SSA) Measurement 
At 4 dpf, larvae were exposed for 24 h in a risperidone or 
fluoxetine solution of 5 μM and at 6 dpf, larvae were 
monitored daily. Animals were placed individually in a 
6-well multiplate at 28˚C. After a 1-min acclimation pe- 
riod, the SSA was measured as the number of times the 
animal crossed the gridlines in 1’ under a magnifying 
glass (Figure 2(a)). For treatments at 4 dpf and 6 dpf or 
only at 6 dpf, at 6 dpf larvae were monitored daily. 
The data was analyzed with Prism GradPad. Experi- 
ments were performed with groups of 6 larvae and the 
data was collected three times per group. 
2.4. Heart Rate Measurements 
The heart rate was assessed at 8 and 10 dpf. Control and 
experimental zebrafish larvae were individually trans- 
ferred to a depression slide with methylcellulose and 
placed under a binocular microscope. The heart rate was 
determined by counting the number of beats per 15 s 
and recorded as beats per minute (bpm). Experiments 
were performed thrice on three larvae per group for 
each time point. 
2.5. Preparation of Histological Sections 
For the fixation of samples, both treated and control 
animals were anesthetized with a tricaine methanesul- 
fonate solution (MS-222, Sigma) at 0.3 g/l. They were 
then fixed by immersion in 4% v/v paraformaldehyde 
(PFA) in phosphate buffer 0.1 M (PB), pH 7.4 for 24 h at 
4˚C. Following fixation, the PFA was removed with five 
5-minute washes in PBS. 
Then the samples were embedded in a mixture 1.5% of 
agar and 10% of sucrose (Panreac) in PB. The mixture 
 
 
Figure 1. Timeline representing the stage specificity of the 
effects of fluoxetine and risperidone in the developing ze-
brafish. Larvae were exposed to 5 μM risperidone and/or 
fluoxetine for 24 h periods from 4 dpf and subsequently 
rescued into a conditioned E3 medium. Larvae were moni-
tored through 9 dpf. 
animals were targeted. After the mixture was solidified, 
the larvae were cryoprotected in a 30% w/v sucrose solu- 
tion in PB for 24 h. Agar blocks containing cryoprotected 
larvae were frozen in a cryostat (Microm HM 560) and 
then cut at –28˚C in 10 µm thick parasaggital serial sec- 
tions, which were collected on gelatinized slides and 
stored at –20˚C until further use. 
2.6. Hematoxylin-Eosin Staining 
Histological sections were obtained as mentioned above 
and stained with hematoxylin-eosin to observe possible 
morphological changes. Briefly, the technique involved 
immersing the sections in eosin for 1 min, then washing 
them with water for 30 min and incubating them for 1 
min in hematoxylin. Finally, the samples were dehy-
drated in alcohols of increasing concentration for 5 min 
each, ending with three tanks of xylene, for 3 min each. 
The slides were mounted in Entellan (Merck) for analysis 
and storage. 
Images of hematoxylin-eosin staining were taken in a 
light microscope (Olympus Provis AX70) coupled to a 
digital camera (DP70, Olympus). 
Finally, to adjust the brightness and contrast of those 
observed directly under the microscope, Adobe® Pho- 
toshop CS2® version 9.0 (Adobe Systems) was used. 
2.7. Immunohistochemistry in Tissue Sections 
The sections were washed three times in PB for 10 min 
to rehydrate and remove the agar and then incubated for 
1 h at room temperature (RT) in non-immune serum 
(Sigma) 5.0%, detergent Triton X-100 (Sigma) 0.2% and 
1.0% DMSO in PB. 
Then, the primary antibodies were added and incu- 
bated for 24 h at RT. After this incubation, the exceeding 
antibodies were removed with three washes of PB and 
then the sections were incubated with the corresponding 
secondary antibodies conjugated with the appropriate 
fluorochrome for 1 h at RT. The secondary antibody was 
removed with three 10-min washes in PB with 0.4% fish 
gelatin (Sigma-Aldrich). 
In order to mark cell nuclei, tissue sections were incu- 
bated in 4’,6-diamidino-2-phenylindole (DAPI, Sigma) at 
a 1:10,000 concentration for 7 min at RT, and then wash- 
ed in PB three times of 10 min each. 
Antibodies Used 
The antibodies used were: 
The polyclonal anti-calretinin (CalR) antibody 7696 (# 
6B3 Swant, Bellinzona, Switzerland), at a 1:10,000 con- 
centration. This antibody has been widely used in the 
study of the neuroanatomy of teleosts, both in adult ani-
mals [21-23] and in embryos, larvae and juveniles [23]. 
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The secondary antibody was labeled with Cy3 (red). 
The anti-tyrosine hydroxylase (TH) antibody (Incstar, 
Stillwater, MN, USA) [24] at a 1:1000 concentration. 
The secondary antibody was labeled with Cy2 (green). 
The sections were examined under a microscope 
(Olympus Provis AX70) coupled to a digital camera 
(XM10, Olympus). The images were coded green (Cy2) 
and red (Cy3), giving yellow co-localization in merged 
images. The images were adjusted for brightness, con- 
trast and colors using Adobe Photoshop 7.0 (Adobe Sys- 
tems). 
2.8. Statistical Analysis 
Data was presented as a mean ± standard deviation (S.D.) 
and analyzed by one-way analysis of variance (ANOVA) 
and Tukey’s Multiple Comparison Test using GraphPad 
Prism v. 5. Only values with P < 0.05 were accepted as 
significant. 
3. Results 
3.1. Heart Rate Measurements 
The effect of fluoxetine and risperidone exposure on cir- 
culation was qualitatively evaluated by observing the 
heart rate and blood flow through the ventral aortaposte- 
rior cardinal vein channel in control versus treated larvae. 
The aim of this study was to determine whether 5 μM 
fluoxetine and/or risperidone affected blood circulation. 
To this end, at 4 and 6 dpf, larvae were exposed to 5 μM 
fluoxetine and/or risperidone for 24 h and their heart rate 
monitored at 8 and 9 dpf. This data demonstrated that 
larvae treated with 5 μM fluoxetine and/or risperidone 
exhibited a normal heart rate at 8 and 9 dpf compared to 
controls (Table 1, P > 0.05). 
Therefore, the effect of 5 μM fluoxetine or risperidone 
on locomotor development in larvae was most likely 
based on neurological grounds rather than on cardiovas-
cular ones. 
3.2. Behavioral Testing 
In this specific experiment, larvae were exposed to 5 μM 
fluoxetine or risperidone at 4 and 6 dpf for 24 h. After 
fluoxetine or risperidone exposure, larvae were rescued 
by transfer into E4 medium. SSA in these larvae was 
monitored daily from 6 to 9 dpf. All SSA measurements 
were performed three times per larva; each data point 
represented the mean ± S.D. of six larvae. 
Risperidone treatment at 4 dpf only transiently de- 
creased SSA, with full recovery after 7 dpf. 
SSA was significantly below that of controls (Figure 
2(b)) in the first days after treatments (6 dpf, P < 0.05). 
After 7 dpf, SSA had recovered to control levels, these 
levels were maintained throughout the remaining experi- 
mental period (Figure 2(b)). 
The same occurred in zebrafish treated with 5 μM ris- 
peridone at 6 dpf and monitored at 8 dpf (8 dpf, P < 
0.05). 
A 24-h exposure to fluoxetine at 4 dpf resulted in a sig-
nificant decrease in SSA as compared to controls (6 dpf, P < 
0.01). SSA recovered fully after 7 dpf, and increased sig-
nificantly at 9 dpf (9 dpf, P < 0.01) (Figure 2 (b)); however, 
the movements were erratic and abnormal. It is worth 
mentioning that when fish were exposed to fluoxetine at 
4 dpf and then to risperidone at 6 dpf, there was no sig-
nificant change in SSA with respect to control (Figure 
2(b)). 
3.3. Tissue Sections 
3.3.1. Morphological Changes 
Both treated and control animals were fixed at 10 dpf, cut 
in serial sections and stained, as mentioned above. A 
24-h exposure to fluoxetine at 4 dpf resulted in an ob- 
servable decrease in the number of nucleated areas of the 
dorsalis telencephali area. The same occurred in the dor- 
sal area of the optic tectum (Figure 3(b)) compared with 
the control (Figure 3(a)). 
There was also a larger area in the postoptic commis- 
sure and the raphe population zone and a cellular disor- 
ganization in the latter. On the other hand, the fissure that 
separates the midbrain at forebrain increased in size 
(Figure 3(b)). All these changes were reflected as an 
increase in abnormal and erratic swimming in the be-
haveioral test. Undoubtedly, the administration of this 
drug to animals at 4 dpf caused dramatic changes that 
persisted overtime. 
In the treatment with risperidone at 4 and 6 dpf (Fig- 
ures 3(c) and (d)), an increase in the nucleated zone of  
 
Table 1. Post-treatment heart rates in zebrafish larvae after a 24 h exposure to 5 μM Fluoxetine or risperidone. A mean num-
ber of heart beats per minute (bpm) (±S.D.) in control and 24 h fluoxetine or risperidone treated zebrafish larvae. There was 
no significant difference between control and fluoxetine or risperidone exposed larvae at either 8 or 9 dpf (P > 0.05, n = 6). 
 Treatment 
Heart rate measurements Prozac 4 dpf Risp 6 dpf Risp 4 dpf Prozac 4 dpf + Risp 6 dpf Control 
8 dpf 121 ± 11 128 ± 7 127 ± 7 131 ± 6 131 ± 9 
9 dpf 115 ± 9 125 ± 7 130 ± 3 121 ± 10 122 ± 6 





Figure 2. (a) Schematic representation of a 6-well multiplate 
with a dividing line for monitoring the spontaneous swim- 
ming activity (SSA); (b) Spontaneous swimming activity 
(SSA) measurements. All SSA measurements began at 6 dpf 
and were performed three times; each data point represents 
the mean ± S.D. of six larvae. 
 
the postoptic commissure and a cellular disorganization 
in the raphe populations zone were observed. However, 
these changes would not be sufficient to affect the SSA. 
Zebrafish exposed to fluoxetine at 4 dpf and then to 
risperidone at 6 dpf showed no significant changes with 
respect to control (Figure 3(e)). 
3.3.2. Immunohistochemistry 
For the histological analysis, crop images were obtained 
to include the reference space area and optical angle for 
brain tissue. In this work, we studied two proteins to de- 
termine dopaminergic neurons, labeled with TH, and 
motoneurons, labeled with CalR. 
When the larvae were exposed to free risperidone, an 
increase in the levels of TH + dopaminergic neurons was 
observed in the dorsal region of the optic tectum of the 
brain (Figures 4(c) and (d)) compared with the control 
(Figure 4(a)). On the other hand, increases in the levels 
of TH + cells in the midbrain region were also observed. 
However, no significant changes in brain tissue (Figures 
4(b) and (e)) were observed with fluoxetine either alone 
or combined with risperidone. 
In the spinal cord, we found a decrease in the levels of 
CalR-positive motoneurons in all treatments with risper- 
idone alone (Figures 5(c) and (d)) compared with the 
control (Figure 5(a)). In the case of fluoxetine, an in-
creased width in the nerve fiber formed by the axons of 
motoneurons (Figure 5(b)) was observed. In the case of 
fish treated with the combination of fluoxetine and ris- 
peridone, there was an increased width in the nerve fiber 
formed by the axons of motoneurons compared with 
those treated with risperidone (Figure 5(e)) but less than 
that found in those under fluoxetine alone. 
 
Figure 3. Images of histological sections of brain tissue stained 
with hematoxylin-eosin. (a) Control; (b) Fluoxetine at 4 dpf; 
(c) Risperidone at 6 dpf; (d) Risperidone at 4 dpf; and (e) 
Fluoxetine at 4 dpf and risperidone at 6 dpf. Larvae were 
analyzed three times (n = 3) at 10 dpf. In Figure 3(b), the 
arrows indicate an observable decrease in the number of 
nucleated areas of the dorsalis telencephali area and the 
optic tectum; also a larger area in the postoptic commissure 
and the raphe population zone and a cellular disorganiza-
tion in the latter. On the other hand, the fissure that sepa-
rates the midbrain at forebrain increased in size. 
 
 
Figure 4. Immunohistochemistry images of brain tissue. 
Tyrosine hydroxylase, labeled with Cy2 (green) and Cal-
retinin labeled with Cy3 (red). (a) Control; (b) Fluoxetine at 
4 dpf; (c) Risperidone at 6 dpf; (d) Risperidone at 4 dpf; and 
(e) Fluoxetine at 4 dpf and risperidone 6 dpf. Larvae were 
analyzed three times (n = 3) at 10 dpf. The arrows in Fig-
ures 4(c) and (d) indicate an increase in the levels of TH + 
dopaminergic neurons in the dorsal region of the optic tec-
tum of the brain and an increase in the levels of TH + cells 
in the midbrain region. 
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Figure 5. Immunohistochemistry images of spinal cord tis-
sue. Tyrosine hydroxylase, labeled with Cy2 (green) and 
Calretinin labeled with Cy3 (red). (a) Control; (b) Fluoxet-
ine at 4 dpf; (c) Risperidone at 6 dpf; (d) Risperidone at 4 
dpf; and (e) Fluoxetine at 4 dpf and risperidone at 6 dpf. 
Larvae were analyzed three times (n = 3) at 10 dpf. In Fig-
ures 5(c) and (d), the arrows indicate a decrease in the lev-
els of CalR-positive motoneurons. In Figures 5(b) and (e) 
the arrows indicate a change in the width of the nerve fiber 
formed by the axons of motoneurons. 
4. Discussion 
In this work, the effects of risperidone and fluoxetine on 
the locomotor activity, heart rate, and brain development 
of zebrafish larvae were studied. These parameters pro- 
vide an idea of the effects caused by serotonin in early 
development stages and provide knowledge on the area 
of neuropharmacology. 
The advantage of studying motoneuron diseases in ze-
brafish [25] is the rapid development of their spinal cord, 
which allows the analysis of motoneuron branching pat-
terns as early as 24 hpf. In addition, responses to touch-
ing and swimming can be monitored after hatching 
around 48 hpf [26]. It is now recognized that zebrafish 
show great similarity to mammals and are an extremely 
useful model for screening compounds at several stages 
of the drug discovery process [27,28]. 
The effect of fluoxetine and risperidone exposure was 
evaluated by examining the heart rate. The results dem- 
onstrated that 5 μM fluoxetine and/or risperidone-treated 
larvae exhibit a normal heart rate at 8 and 9 dpf com- 
pared to controls. When larvae were exposed to 5 μM 
fluoxetine and/or risperidone at 4 and 6 dpf and for 24 h, 
SSA was monitored daily from 6 to 9 dpf. SSA was sig- 
nificantly lower than controls on the first days after 
treatments. After 7 dpf, SSA levels recovered up to those 
of control, and were maintained throughout the remain- 
ing experimental period under risperidone treatment. In 
larvae exposed to 5 μM fluoxetine alone, SSA was sig- 
nificantly increased at 9 dpf as compared to controls. 
However, erratic and abnormal movements were ob- 
served with this increase, suggesting a long-term toxic 
effect of fluoxetine. The unusual body position exhibited 
in swimming during the behavioral test after exposure to 
fluoxetine was also observed. While control animals 
maintained a parallel position with respect to the water 
surface when swimming, the animals treated with fluoxe- 
tine were unable to maintain such a position, indicating 
lack of postural balance, as described in previous studies 
[29]. In addition, we found that fluoxetine-treated zebra- 
fish exhibited erratic swimming patterns, manifested by 
bouts of vertical swimming or sideway swimming, sug-
gesting a coordination problem. This extended effect 
suggests that fluoxetine effect is not pharmacological, but 
rather developmental. However, when fish were treated 
with fluoxetine and risperidone, SSA showed no signifi-
cant differences with control, and no erratic swimming 
was observed. This result suggests a reversible process, 
given that fluoxetine increases the levels of serotonin and 
risperidone levels out this effect. So, it is important to 
note that changes in SSA are not pharmacological be-
cause for extended periods of time, the effects are re-
versed when the concentrations of the neurotransmitter 
are decreased. 
Representatives from all major fish classes possess se- 
rotonergic neurons in the raphe nuclei, giving rise to as- 
cending and descending pathways [18,30-47]. Due to 
their apparent resemblance with the mammalian raphe 
serotonergic neurons, these are the best studied popula- 
tions within fish. Generally, the assumption for teleosts 
has been that the two raphe nuclei (superior and inferior 
raphe) innervate most brain areas in a manner similar to 
that described for mammals and, accordingly, that they 
may play equivalent functional roles. Indeed, 5-HT im- 
munoreactive fibers have been detected throughout the 
fish CNS [30,33,37,39,41,42,48-51]. 
The raphe serotonergic innervation of the zebrafish 
dorsal telencephalon, in particular of the lateral zone, is 
very dense. Further, Lillesaar et al. [18] observed few 
serotonergic fibers in the medial zone of the dorsal tel- 
encephalon originating from the raphe fibers. Interest- 
ingly, developmental studies in zebrafish as well as ax- 
onal tracing and lesion experiments combined with be- 
havioral assays performed in goldfish suggest that these 
areas are functionally equivalent to the mammalian hip- 
pocampus and amygdala, respectively [52-54]. In mam- 
mals, the hippocampus is involved in spatial, contextual, 
or relational memory and it is known to be supplied by a 
rich serotonergic innervation mainly from the median 
raphe populations [55,56]. 
Several antipsychotic drugs cause a neurotoxic mecha- 
nism resulting from an increased or decreased concentra- 
tion of serotonin both in the synaptic and extracellular 
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spaces. In this sense, drug exposure at 4 or 5 dpf coin- 
cides with the initial appearance of inferior raphe axons 
distributed throughout the entire length of the spinal cord 
in zebrafish [7]. Growth cones of these axons at 4 dpf 
have been observed adjacent to reticulospinal neurons in 
the hindbrain and secondary motoneurons in the spinal 
cord. The temporal correlation between the growth of 
inferior raphe axons and growth cones throughout the 
spinal cord and the earliest morphological effects of an-
tipsychotics drugs suggest that raphe axons are affected 
by the exposure to these drugs. The mechanism of excess 
or default of serotonin toxicity has been elusive. Consid-
ering the temporal correlation between the development 
of the inferior raphe pathway and risperidone exposure, it 
was surprising to find no change in SSA. The transient 
depression of SSA in larvae exposed to risperidone at 4 
and 6 dpf may be due to the long half-life of the drug 
[57]. When the larvae were exposed to fluoxetine alone, 
first a decrease in swimming and then an increase with 
erratic movements were noted. However, in zebrafish 
exposed to fluoxetine at 4 dpf and then to risperidone at 6 
dpf, there was no significant change with respect to con- 
trol, indicating a possible reversal of the effects caused 
by exposure to fluoxetine observed previously. 
In immunohistochemical assays, we used two proteins 
to determine dopaminergic neurons, labeled with tyrosine 
hydroxylase (TH) and motoneurons, labeled with cal- 
retinin (CalR). TH is the first enzyme in the catechola- 
mine synthesis pathway [58]. TH has also been described 
to be involved in the stabilization of dopamine synapses 
[59]. When the larvae were exposed to free risperidone, 
several changes in the brain were observed. This could 
be because the drug is a strong blocker of dopamine re- 
ceptors, which would affect dopaminergic neurons. 
However, despite the changes observed in the distribu- 
tion pattern of dopaminergic neurons, these would not 
affect the SSA. On the other hand, when administered 
fluoxetine alone or fluoxetine and risperidone, there were 
no changes with respect to the control. These results in- 
dicate that risperidone alone increased the levels of TH 
enzymes of the dopaminergic cells when administered as 
a single drug. 
CalR was found in several neuronal populations of the 
central and peripheral nervous system, primarily in mo- 
toneurons and other sensory pathways [60]. CalR is a 
cytosolic protein of 29-kD, belonging to the family of 
calcium-binding proteins “EF hand” [61], these ex- 
pressed during early development of the CNS of verte- 
brates [62], although CalR needs some degree of cell 
differentiation and tissue to be expressed [63]. Cal- 
cium-binding proteins buffer intracellular calcium, thus 
contributing to the properties of neuronal membranes and 
their electrical activity. In the spinal cord, we found a 
decrease in the number of CalR-positive motoneurons in 
all treatments with free risperidone. These changes could 
be due to the effect of risperidone on the core neural mi- 
gration raphe (located in the hypothalamus) to the spinal 
cord. This migration begins to be observed between 2 
and 3 dpf and extends into the caudal spinal cord after 4 
days [7]. In the case of fluoxetine, an increase in the 
width of nerve fiber formed by the axons of motoneurons 
was observed. This could cause a significant increase in 
SSA at 9 dpf with erratic and abnormal movements, 
given the potential neurotoxicity of the drug. In this re- 
spect, antipsychotic drugs could alter the extracellular 
levels of neurotransmitters and thereby modify the de- 
velopment of the CNS [7,14,28,64]. These changes sug- 
gest that the neuroanatomy is affected by fluoxetine and 
risperidone exposure, since these changes are not suffi- 
cient to modify the SSA in the case of risperidone. 
According to Seibt et al. [28], antipsychotic drugs 
show high affinity for biomembranes due to their am- 
phiphilic property. This implies that antipsychotic drugs 
can also interact with membrane lipid organization. The 
intercalation of antipsychotic drug molecules into the 
plasma membrane can modify the membrane lipid dy- 
namics, inducing a subsequent modification of the re- 
ceptor response [64]. Drug interaction elicits short and 
long range influence on the bilayer structure, cones- 
quently, modulating processes that range from mem- 
brane-bound enzyme activity and receptor binding to 
membrane permeability and transport [65]. The inter- 
calation of antipsychotic drug molecules into the plasma 
membrane may thus modulate the efficacy and tolerabil-
ity profile of compounds able to exert their therapeutic 
effect through their binding with synapse receptors. This 
suggests that the pharmacological activity of antipsy- 
chotic medications may result from a combination of 
drug-receptor and drug-membrane interactions [66]. Gi- 
acomini et al. [29] have suggested that the pharmacol- 
ogical actions of these antipsychotic drugs may be well 
retained in vertebrates. 
Studies in zebrafish will provide an important insight 
into the side effects of these drugs as well as into the 
brain control of locomotor activity. 
Testing several drug-induced changes in behavioral 
and serotonin levels is one of the experimental approaches 
for screening a new therapeutically relevant compounds, 
and merits further research in this animal model. 
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Hpf: Hours Post Fertilization; 
Dpf: Days Post Fertilization; 
SSA: Spontaneous Swim Activity; 
TH: Tyrosine Hydroxylase; 
CalR: Calretinin; 
CNS: Central Nervous System; 
ASD: Autism Spectrum Disorders; 
SSRI: Selective Serotonin Reuptake Inhibitor; 
Risp: Risperidone; 
LOEC: Lowest Observable Effective Concentration; 
bpm: Beats Per Minute; 
PB: Phosphate Buffer 0.1 M; 
PFA: 4% v/v Paraformaldehyde; 
RT: Room Temperature; 
MLF: Medial Longitudinal Fascicle. 
